Lilly Buying SGX For $64M In Cash
This article was originally published in The Pink Sheet Daily
Executive Summary
2003 partnership turns into takeover for structural biology firm.
You may also be interested in...
Let’s Make A Deal: Lilly Won’t Up SGX Bid Of $64 Million
$3 per share is Lilly’s best and final offer for the San Diego biotech.
Let’s Make A Deal: Lilly Won’t Up SGX Bid Of $64 Million
$3 per share is Lilly’s best and final offer for the San Diego biotech.
SGX Pharmaceuticals Reports Toxicity With Lead Oncology Candidate In Phase I
CEO Grey acknowledges setback but points to second MET inhibitor and Novartis-partnered BCR-ABL inhibitor program as promising.